Can umbilical cord stem cells ease a scarring lung disease?

NCT ID NCT06230822

Completed Disease control Sponsor: Wuhan Optics Valley Vcanbiopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This early-stage trial is testing an experimental stem cell therapy called VUM02 in people with idiopathic pulmonary fibrosis (IPF), a condition that causes progressive lung scarring and breathing difficulty. The study aims to see if the treatment is safe and tolerable, and whether it might help improve lung function. Participants receive three intravenous doses of the stem cells, with the dose gradually increasing across small groups to find the safest level.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VUM02 Injection (Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells)
What this could lead to: If safe and effective, this stem cell therapy could offer a new way to slow or ease the progression of idiopathic pulmonary fibrosis, a disease with limited treatment options.
What could go wrong: This is an early, small phase 1 trial focused on safety, so it may not prove effective. There are also risks of side effects from the cell therapy itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS

Contacts and locations

Locations

Peking University Third Hospital

Beijing, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, China
The First People's Hospital of Kashi Prefecture, Xinjiang

Kashgar, China
West China Hospital of Sichuan University

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.